It took 14 years for Oklahoma City biotechnology company InterGenetics to research and develop its breast cancer risk assessment test, OncoVue. But less than a year after becoming commercially available, the test has already begun paying dividends to patients. A California oncologist reports that that the test, which has its origins in research conducted at […]
✕
